<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446026</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-0488</org_study_id>
    <nct_id>NCT04446026</nct_id>
  </id_info>
  <brief_title>A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen</brief_title>
  <official_title>A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled clinical trial of Teneligliptin as quadruple oral&#xD;
      combination therapy for type 2 diabetes after failure of an oral triple anti-diabetic&#xD;
      regimen. Patients with uncontrolled type 2 diabetes (7.1% ≤ HbA1c ≤ 9%) prescribed with&#xD;
      triple combination of oral antidiabetic drugs more than 12 weeks with sufficient doses&#xD;
      (metformin &gt;= 1000mg/d, Glimepiride &gt;=4 mg/day, Gliclazide &gt;= 60 mg/day, SGLT-2 inhibitor&#xD;
      with approved dose by Korea FDA) will be included. Using randomization, patients would take&#xD;
      either teneligliptin (20mg) or placebo for 12 weeks. After 12 weeks of trial, all patients&#xD;
      would receive teneligliptin for another 12 weeks. As outcomes, changes in HbA1c and fasting&#xD;
      plasma glucose at 12th and 24th weeks compared with at baseline, and proportions of patients&#xD;
      who achieved a glycemic goal (HbA1c &lt;=7%) at 12th and 24th weeks will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Actual">May 17, 2021</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hb1Ac</measure>
    <time_frame>12 weeks</time_frame>
    <description>Difference between baseline and HbA1c at 12 weeks after treatment with test drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>24 weeks</time_frame>
    <description>Difference between baseline and HbA1c at 24 weeks after treatment with test drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who reached target blood glucose (6.5% or 7% as HbA1c)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of patients who reached target blood glucose (6.5% or 7% as HbA1c) at 12 and 24 weeks after treatment with the test drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who reached target blood glucose (6.5% or 7% as HbA1c)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of patients who reached target blood glucose (6.5% or 7% as HbA1c) at 12 and 24 weeks after treatment with the test drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting blood glucose (FPG) at 12 and 24 weeks after treatment with test drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fasting blood glucose (FPG) at 12 and 24 weeks after treatment with test drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>teneligliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teneligliptin</intervention_name>
    <description>teneligliptin 20mg PO qd for 24weeks</description>
    <arm_group_label>teneligliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age over 18 years and less than 81 years&#xD;
&#xD;
          2. Patients with type 2 diabetes prescribed with triple combination of oral antidiabetic&#xD;
             drugs more than 12 weeks with sufficient doses (metformin &gt;= 1000mg/d, Glimepiride &gt;=4&#xD;
             mg/day, Gliclazide &gt;= 60 mg/day, SGLT-2 inhibitor with approved dose by Korea FDA)&#xD;
&#xD;
          3. Uncontrolled hyperglycemia with 7.1% ≤ HbA1c ≤ 9% at randomization period&#xD;
&#xD;
          4. Recommended to use insulin by physicians&#xD;
&#xD;
          5. Patients able to understand study protocol and cooperative&#xD;
&#xD;
          6. Voluntary consent to participation of study after understanding study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes, gestational diabetes, other than type 2 diabetes&#xD;
&#xD;
          2. Insulin treatment more than 1 week (not necessarily continuous use) prior to screening&#xD;
             visit within 1 year&#xD;
&#xD;
          3. Hypersensitivity to TENELIA tablet including main and other component&#xD;
&#xD;
          4. Use of DPP4 inhibitor more than 1 week prior to screening visit within 3 months or&#xD;
             discontinuation of DPP4 inhibitor due to severe side effects regardless of treatment&#xD;
             period&#xD;
&#xD;
          5. History of acute or chronic metabolic acidosis and ketosis including diabetic&#xD;
             ketoacidosis with/without comma prior to screening visit within 12 weeks&#xD;
&#xD;
          6. Genetic trait of galactose intolerance, Lapp lactase deficiency, or glucose-galactose&#xD;
             mal-absorption&#xD;
&#xD;
          7. Difficulty in oral ingestion of drug owing to anatomical abnormalities in head and&#xD;
             neck area, or owing to abnormalities in central nervous system&#xD;
&#xD;
          8. Steroid use including per oral and non-oral more than 14 consecutive days prior to&#xD;
             screening visit within 8 weeks (inhaled steroid use is permitted)&#xD;
&#xD;
          9. Histories of any malignancy prior to screening visit within 5 years&#xD;
&#xD;
         10. History of congestive heart failure (&gt;= 10) NYHA class III)&#xD;
&#xD;
         11. Uncontrolled arrhythmia, unstable angina, myocardial infarction, stroke, transient&#xD;
             ischemic attack, cerebrovascular disease prior to screening visit within 24 weeks&#xD;
&#xD;
         12. Initiation of statin to treat dyslipidemia prior to screening visit within 4 weeks or&#xD;
             anticipated increasing dose of statin during study period&#xD;
&#xD;
         13. Renal failure, chronic kidney disease stage &lt;=3 (estimated glomerular filtration rate&#xD;
             &lt;30 mL/min/1.73 m2, calculated using EKD-EPI) or patients with dialysis&#xD;
&#xD;
         14. Abnormalities in liver function test: AST, ALT, or ALP &gt;= 2.5 fold of ULN or patients&#xD;
             with liver cirrhosis (Child-Pugh class B or C)&#xD;
&#xD;
         15. Infection of HIV, HBV, or HCV and patients subjected to anti-viral therapy within 1&#xD;
             year&#xD;
&#xD;
         16. Pregnant or lactating women; or planning to be pregnant&#xD;
&#xD;
         17. Patients with other severe infection or with severe injuries, or patients expecting&#xD;
             any surgery with transient insulin use for peri-operational glucose control&#xD;
&#xD;
         18. Alcohol or any psychotropic substances dependancy , or dependency of any unapproved&#xD;
             substances&#xD;
&#xD;
         19. Last visit of other clinical trials for treatment purposes prior to screening visit&#xD;
             within 30 days&#xD;
&#xD;
         20. Other inappropriate properties judged by researchers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

